Early Insight Into the Retrospective Data of a Case Series on Type 2 Diabetes Mellitus on Alternate-Day Dosing of Oral Semaglutide: Utopia or Reality?

Introduction Oral semaglutide, with a long half-life of seven days, is the first oral-based peptide drug and is used as an antidiabetic for the reduction of glycosylated hemoglobin (HbA1c). Oral semaglutide, like other glucagon-like peptide-1 receptor agonists (GLP1RAs), is costly and has gastrointe...

Descripción completa

Detalles Bibliográficos
Autores principales: RoyChaudhuri, Soumyabrata, Majumder, Anirban, Sanyal, Debmalya, Chakraborty, Soma, Chuyan, Susama
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Endocrinology/Diabetes/Metabolism
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10155755/
https://www.ncbi.nlm.nih.gov/pubmed/37153287
http://dx.doi.org/10.7759/cureus.37065

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10155755/
https://www.ncbi.nlm.nih.gov/pubmed/37153287
http://dx.doi.org/10.7759/cureus.37065

Ejemplares similares